All Content © 2003-2011, Portfolio Media, Inc.
Law360, New York (December 16, 2011, 3:09 PM ET) -- Settlements of Hatch-Waxman litigation between branded and generic pharmaceutical companies that include a “reverse payment” by the branded firm to the generic have been the subject of significant antitrust litigation over the past several years.
Courts have not tended to use either a “per se” or “rule of reason” analysis, instead adopting a “scope of the patent” test to review such settlements.
Read the full article by clicking the link below.
Scrutinizing Reverse-Payment Settlements
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.